Andrew Pannifer
About Andrew Pannifer
Andrew Pannifer is the Director of Computational Drug Design at Exscientia in Oxford, England. He has a strong background in protein crystallography and cheminformatics, with previous roles at Pfizer and Medicines Discovery Catapult.
Current Role at Exscientia
Andrew Pannifer serves as the Director of Computational Drug Design at Exscientia, a position he has held since 2021. Based in Oxford, England, he is involved in various computational drug design projects. His role focuses on leveraging computational techniques to enhance drug discovery processes, contributing to the development of innovative therapeutics.
Previous Experience in Drug Design
Prior to joining Exscientia, Andrew Pannifer worked at Medicines Discovery Catapult as Head of Cheminformatics from 2017 to 2021. In this role, he led initiatives in cheminformatics, applying his expertise to support drug discovery efforts. His earlier experience includes a position at Pfizer as a Protein Crystallographer from 2004 to 2010, where he contributed to protein structure analysis for drug design.
Educational Background
Andrew Pannifer studied at the University of Oxford, where he earned a Bachelor of Arts in Biochemistry from 1989 to 1993. He furthered his education at the same institution, obtaining a D.Phil in Protein Crystallography from 1994 to 1998. This academic foundation has supported his extensive career in drug design and cheminformatics.
Expertise in Protein Crystallography
Andrew Pannifer has a strong background in protein crystallography, having worked in this field at both Syngenta Crop Protection from 2002 to 2004 and Pfizer. His expertise in this area has been instrumental in contributing to structure-based drug design (SBDD) projects, enhancing the understanding of protein structures to inform drug development.
Cheminformatics and Computational Drug Design
Throughout his career, Andrew Pannifer has developed significant expertise in cheminformatics, applying this knowledge in both academic and industry settings. His experience encompasses a range of computational drug design projects, particularly during his tenure at Exscientia, where he utilizes advanced computational methods to facilitate drug discovery.